Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TLSI

TriSalus Life Sciences Inc

Mar 06 • 04:00PM ET

4.47

-0.30 -6.39 %

Healthcare • Medical Devices • USA • NASD

Peers: CRSP NTLA FATE IMTX EDIT BLUE SGMO ADAP CELU SLDB

| Held by: VTI IWM VXF IWN VTWO IWC IWO VTWV RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.83	Insider Own	39.43%	Shs Outstand	50.00M	Perf Week	-11.76%
Market Cap	273.73M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	1.83%	Shs Float	37.13M	Perf Month	-9.06%
Enterprise Value	287.73M	PEG	-	EPS next Q	-0.15	Inst Own	19.14%	Short Float	3.13%	Perf Quarter	-30.56%
Income	-71.12M	P/S	6.06	EPS this Y	80.71%	Inst Trans	4.35%	Short Ratio	6.49	Perf Half Y	-13.30%
Sales	45.15M	P/B	-	EPS next Y	59.15%	ROA	-132.30%	Short Interest	1.16M	Perf YTD	-36.03%
Book/sh	-0.68	P/C	13.39	EPS next 5Y	-	ROE	-	52W High	7.95 -43.84%	Perf Year	-21.11%
Cash/sh	0.33	P/FCF	-	EPS past 3/5Y	77.50% -140.62%	ROIC	-17219.37%	52W Low	3.42 30.56%	Perf 3Y	-55.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	53.85% -	Gross Margin	84.19%	Volatility	7.95% 7.53%	Perf 5Y	-54.90%
Dividend TTM	-	EV/Sales	6.37	EPS Y/Y TTM	-37.31%	Oper. Margin	-59.68%	ATR (14)	0.39	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.54	Sales Y/Y TTM	53.41%	Profit Margin	-157.51%	RSI (14)	37.71	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.80	EPS Q/Q	47.33%	SMA20	-8.96%	Beta	0.45	Target Price	10.12
Payout	-	Debt/Eq	-	Sales Q/Q	59.85%	SMA50	-17.87%	Rel Volume	4.23	Prev Close	4.77
Employees	102	LT Debt/Eq	-	Earnings	Mar 05 AMC	SMA200	-14.00%	Avg Volume	178.88K	Price	4.47
IPO	Feb 08, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-47.89% 3.04%	Trades		Volume	756,063	Change	-6.39%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-11-24	Initiated	ROTH MKM	Buy	$11
Oct-25-24	Initiated	Northland Capital	Outperform	$12.50
Sep-16-24	Initiated	Oppenheimer	Outperform	$10
May-30-24	Initiated	Canaccord Genuity	Buy	$12

Mar-06-26 08:30AM	TriSalus Life Sciences, Inc. Q4 2025 Earnings Call Summary (Moby) -6.39%
12:10AM	TriSalus Life Sciences Q4 Earnings Call Highlights (MarketBeat)
12:01AM	TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-05-26 04:01PM	TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance (Business Wire)
Mar-04-26 07:22AM	TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
04:05PM	Loading…
Feb-25-26 04:05PM	TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call (Business Wire)
Feb-20-26 08:00AM	TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering (Business Wire) +18.22%
Feb-19-26 04:01PM	TriSalus Life Sciences Proposes Public Offering (Business Wire)
Feb-09-26 09:00AM	TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors (Business Wire)
Jan-14-26 12:00PM	TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-12-26 07:00AM	TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance (Business Wire)
Dec-04-25 04:01PM	TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 (Business Wire) +5.37%
Nov-18-25 08:00AM	TriSalus Life Sciences Launches TriNav XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery (Business Wire)
Nov-14-25 12:04AM	TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-13-25 05:15PM	TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance (Business Wire)
Nov-12-25 07:29AM	TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:10AM	Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-11-25 04:05PM	TriSalus Life Sciences to Participate in Upcoming Investor Conferences (Business Wire) +8.50%
Nov-10-25 08:00AM	TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025 (Business Wire) -8.88%
Nov-06-25 07:00PM	ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-05-25 06:15PM	biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.32%
Oct-30-25 08:00AM	TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call (Business Wire)
Aug-28-25 08:00AM	TriSalus Life Sciences to Participate in Upcoming September Investor Conferences (Business Wire)
Aug-13-25 03:12AM	TriSalus Life Sciences Inc (TLSI) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.22%
Aug-12-25 05:10PM	TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance (Business Wire)
Aug-11-25 07:00PM	Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.62%
09:37AM	Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q2 2025 Result (GuruFocus.com)
08:00AM	TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique (Business Wire)
07:40AM	Loading…
Aug-07-25 07:40AM	Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates (Zacks) -7.09%
Jul-30-25 04:05PM	TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call (Business Wire)
Jul-24-25 05:58PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock (Business Wire)
Jun-23-25 05:30PM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure (Business Wire) -5.37%
Jun-04-25 08:00AM	TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System (Business Wire)
May-30-25 07:00AM	TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience (Business Wire) -8.76%
May-16-25 03:01PM	TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-15-25 08:10AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance (Business Wire)
May-12-25 07:15PM	OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised) (Zacks)
04:30PM	TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call (Business Wire)
07:45AM	OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-08-25 06:45PM	TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.31%
08:00AM	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results (Business Wire)
Apr-10-25 11:33AM	VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? (Zacks)
Apr-09-25 08:47AM	TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Mar-30-25 08:02AM	TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks (Seeking Alpha)
Mar-27-25 02:02PM	TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:40AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 08:00AM	TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav Infusion System Mapping (Business Wire)
Mar-06-25 08:00AM	TriSalus Life Sciences Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model" (Business Wire)
Feb-03-25 04:05PM	TriSalus Life Sciences Announces Key Appointments to Board of Directors (Business Wire)
08:00AM	TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed (Business Wire)
Jan-23-25 08:00AM	TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call (Business Wire) +5.31%
Jan-10-25 08:30AM	TriSalus Life Sciences announces publication of pre-clinical data (TipRanks) +7.95%
Jan-09-25 08:00AM	TriSalus Life Sciences Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres to Liver Tumors using Pressure-Enabled Drug Delivery (PEDD) via the TriNav Infusion System (Business Wire)
Jan-08-25 08:00AM	TriSalus Announces Leadership Changes (Business Wire) -7.18%
Nov-14-24 08:00AM	TriSalus Reports Q3 2024 Financial Results and Provides Business Update (Business Wire) -10.89%
Nov-13-24 07:27AM	TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-11-24 07:00AM	TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer (Business Wire) +5.91%
Nov-07-24 07:00AM	TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment (Business Wire)
Oct-31-24 08:00AM	TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call (Business Wire)
Oct-14-24 04:05PM	TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-26-24 07:00AM	TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board (Business Wire)
Sep-23-24 07:00AM	TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System (Business Wire) -6.70%
Sep-14-24 01:52AM	TriSalus Life Sciences Inc (TLSI) CEO Buys Shares (GuruFocus.com)
Aug-15-24 08:00AM	TriSalus Reports Q2 2024 Financial Results and Business Update (Business Wire)
Aug-01-24 07:00AM	TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call (Business Wire)
Jul-01-24 04:00PM	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation (Business Wire) -5.07%
Jun-26-24 05:45PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire)
Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%
Nov-14-23 12:27PM	TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023 (GuruFocus.com)
08:00AM	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-07-23 04:05PM	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call (Business Wire) -5.39%
Nov-04-23 02:25PM	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications (Business Wire)
Nov-03-23 12:00PM	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire) +12.90%
Oct-25-23 09:05AM	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Business Wire)
Sep-06-23 07:00AM	TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics (Business Wire) -6.96%
Aug-10-23 04:05PM	TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation (Business Wire) +18.67% +5.82%
Aug-02-23 05:00PM	MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders (Business Wire) -5.60%
Jun-12-23 07:00AM	TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting (Business Wire)
Apr-20-23 07:00AM	TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases (Business Wire)

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patience David	Chief Financial Officer	Feb 23 '26	Buy	4.10	3,657	14,994	268,657	Feb 23 04:08 PM
Gordon Gary B.	Director	Feb 23 '26	Buy	4.10	9,756	40,000	9,756	Feb 23 04:08 PM
Valle William	Director	Feb 23 '26	Buy	4.10	30,487	124,997	30,487	Feb 23 04:08 PM
Szela Mary T	CEO and President	Feb 23 '26	Buy	4.10	30,487	124,997	773,289	Feb 23 04:08 PM
Stansky Michael P	Director	Feb 23 '26	Buy	4.10	243,900	999,990	787,132	Feb 23 04:08 PM
Stansky Michael P	Director	Feb 23 '26	Buy	4.10	117,198	480,512	199,698	Feb 23 04:08 PM
Cox Bryan F.	Chief of Research	May 19 '25	Sale	5.18	4,764	24,678	119,415	May 21 05:33 PM
Devlin Jodi	Chief of Clinical Operations	May 19 '25	Sale	5.18	4,764	24,678	52,764	May 21 05:31 PM
Marshak Richard	Chief Commercial Officer	May 19 '25	Sale	5.18	6,597	34,172	69,101	May 21 05:30 PM
Stevens Jennifer	Chief Regulatory Officer	May 19 '25	Sale	5.18	8,704	45,087	77,640	May 21 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSI

TriSalus Life Sciences Inc

Upgrade your FINVIZ experience